Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10820255 | 1.00 | LTB4R (0.43) | LTB4RLTB4R2HCRTR2DRD2DRD3 | |
| SCHEMBL18570198 | 1.00 | LTB4R (0.43) | LTB4RLTB4R2HCRTR2DRD2DRD3 | |
| SCHEMBL13117931 | 1.00 | LTB4R (0.43) | LTB4RLTB4R2HCRTR2DRD2DRD3 | |
| SCHEMBL29259098 | 0.82 | CYP2D6 (0.51) | SLC6A2CYP2D6SLC6A4CYP19A1SLC6A3 | |
| SCHEMBL12216729 | 0.78 | ABCB1 (0.42) | LTB4RLTB4R2HCRTR2DRD2DRD3 | |
| SCHEMBL12727583 | 0.78 | ITGB2 (0.46) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL2739937 | 0.78 | ABCB1 (0.42) | LTB4RLTB4R2HCRTR2DRD2DRD3 | |
| SCHEMBL2616050 | 0.78 | ITGB2 (0.46) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL30388151 | 0.78 | ITGB2 (0.46) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL13117930 | 0.78 | ITGB2 (0.46) | ABCG2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | claimed |
| US-10693080-B2 | Solvent for producing organic transistor | DAICEL CORPORATION (JP) | 2020-06-23 | — | — | US | claimed |
| CN-105659404-B | Solvent for manufacturing organic transistor | 株式会社大赛璐 | 2020-02-07 | — | — | CN | claimed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | claimed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | claimed |
| US-20160293849-A1 | SOLVENT FOR PRODUCING ORGANIC TRANSISTOR | DAICEL CORPORATION (JP) | 2016-10-06 | — | — | US | claimed |
| CN-105659404-A | Solvent for producing organic transistor | 株式会社大赛璐 | 2016-06-08 | — | — | CN | claimed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | claimed |
| US-4888353-A | Carboxamides useful as antiemetic or antipsychotic agents | ERBAMONT, INC. (US) | 1989-12-19 | — | — | US | claimed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023183613-A2 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR INFLAMMATION | TACTOGEN INC (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1044985-A1 | ERYTHROMYCIN DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160293849-A1 | SOLVENT FOR PRODUCING ORGANIC TRANSISTOR | SCO2, SLCO2A1, OXSR1 | LTB4R 256/4885LTB4R2 486/4885HCRTR2 1436/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | LTB4R 4062/4885LTB4R2 4129/4885HCRTR2 4016/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | LTB4R 3955/4885LTB4R2 2763/4885HCRTR2 70/4885 |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | LTB4R 2842/4885LTB4R2 3632/4885HCRTR2 3426/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | LTB4R 2842/4885LTB4R2 3632/4885HCRTR2 3426/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | LTB4R 3955/4885LTB4R2 2763/4885HCRTR2 70/4885 |
| US-10693080-B2 | Solvent for producing organic transistor | SCO2, SLCO2A1, OXSR1 | LTB4R 256/4885LTB4R2 486/4885HCRTR2 1436/4885 |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | LTB4R 1554/4885LTB4R2 2262/4885HCRTR2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.